It is indicated that IRF1-dependent chromatin and transcriptional regulation contribute to the diverse anti-tumor effects of ATRA and provide a framework for biomarker-guided evaluation of ATRA in cancer therapies.
Abstract
All-trans retinoic acid (ATRA) is a potent differentiation inducer successfully used to treat acute promyelocytic leukemia (APL), with its therapeutic efficacy traditionally attributed to targeting the PML/RARα fusion oncoprotein. ATRA also exhibits anti-tumor activity in multiple non-APL malignancies. However, PML/RARα targeting alone does not fully explain the diverse ATRA-induced anti-tumor responses, and the early transcriptional regulators coordinating these responses remain incompletely understood. Here, we performed a time-series transcriptomic analysis in an ATRA-sensitive APL cell line and identified interferon regulatory factor 1 (IRF1) as a pivotal early regulator of ATRA response that orchestrates multiple downstream transcriptional programs. Mechanistically, chromatin immunoprecipitation sequencing (ChIP-seq) revealed that ATRA enhanced IRF1 chromatin occupancy and transcriptional activity, thereby activating gene networks linked to ATRA-induced myeloid differentiation, proliferation control, cell-cycle regulation, and the reformation of promyelocytic leukemia (PML) nuclear bodies. Further IRF1 knockdown markedly impaired these phenotypic effects, confirming its essential role in coordinating ATRA-induced cell fate transitions. Moreover, cross-cancer studies demonstrated that IRF1 activation and the associated IRF1-dependent transcriptional signatures were selectively enriched in ATRA-sensitive tumors but not in ATRA-resistant contexts. Leveraging this shared regulatory mechanism, we developed an IRF1_ATRA score that could predict tumor responsiveness to ATRA across hematopoietic and solid malignancies, thereby supporting the expansion of ATRA-based therapy to a broader range of cancers. Collectively, our findings indicate that IRF1-dependent chromatin and transcriptional regulation contribute to the diverse anti-tumor effects of ATRA and provide a framework for biomarker-guided evaluation of ATRA in cancer therapies.
Breast cancer remains the most prevalent malignancy among women worldwide, yet robust molecular biomarkers are still lacking to advance precision oncology. Integrative analyses of our single-cell RNA sequencing (scRNA-seq) and mRNA microarray datasets identified endocytic protein, the short isoform of intersectin 1...
Hui-Kun Zhang, Si-Qing Sun, Ya-Wen Zhao et al.· Cell Death & Disease· 0 citations
Summary Although nuclear receptor subfamily 2 group F member 6 (NR2F6) regulates lymphocyte activation in murine models, its function in human T cells remains incompletely defined. Here, we identify NR2F6 as a T cell receptor (TCR)-inducible transcriptional checkpoint that limits effector potency in human CD3+ T cells,...
Jiří Koutník, Thomas Gruber, D. Freimark et al.· iScience· 1 citation
This study uncovers a previously undescribed DCBLD2-centered regulatory cascade that promotes colorectal cancer initiation and progression and represents promising prognostic biomarkers and actionable therapeutic targets for colorectal cancer.
Tong Wu, Lan Shao, Xin Hu et al.· Molecular Biomedicine· 0 citations
DNA-proximal phosphorylation of MYB is identified as a critical regulatory mechanism required for MYB oncogenesis through cooperative organization of transcription factors and nominated MYB N-terminal phosphorylation and its upstream kinases as candidate therapeutic targets for MYB-dependent leukemia.
Shu-Yuan Cheng, Katarzyna Kulej, Masahiro Uni et al.· Cancer Research· 0 citations